NCT01472731View on ClinicalTrials.gov

Safety and Imaging Study of GC1008 in Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Primary Brain Tumors
Interventions
OTHER

89Zr-GC1008

radioactive labeled GC1008, intravenous use, 37 MBq total

DRUG

GC1008

5 mg/kg intravenous use

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT01472731 - Safety and Imaging Study of GC1008 in Glioma | Biotech Hunter | Biotech Hunter